Lupin and Boehringer Ingelheim join hands to develop anti-cancer drug
Category: #headline  By Mateen Dalal  Date: 2019-09-05
  • share
  • Twitter
  • Facebook
  • LinkedIn

Lupin and Boehringer Ingelheim join hands to develop anti-cancer drug
  • The 2 major companies have inked a deal valued at USD 700 million for the development of the cancer drug.
     
  • Lupin to receive royalty on the sales of the drug developed while retaining the commercial rights to the program in India.

Multinational pharmaceutical company, Lupin Limited has recently inked a USD 700 million deal with a German drug maker company Boehringer Ingelheim to manufacture an advanced anti-cancer drug for chronic cancer patients.

It has been reported that the Indian company would receive forthright installment of USD 20 million with the additional payments of more than over USD 700 million on the successful accomplishment of agreed clinical, administrative and business achievements.  

Nilesh Gupta, the managing director of Lupin was reportedly quoted stating that the company has marked a significant contribution towards bringing novel treatments to the patients owing to its discovery of the advanced cancer drug. Additionally, Lupin’s MEK Inhibitor program positively cleared the initial clinical stages, showcasing its capabilities in delivering the world class innovation.

Apparently, the company is looking forward to developing its MEK inhibitor complex in association with one of Boehringer Ingelheim’s protein coding KRAS inhibitors for metastatic colorectal cancer patients possessing a high range of oncogenic KRAS mutations.

As per trusted reports, KRAS mutation takes place in over one in seven of humane metastatic cancers making it the commonly mutated cancer-causing gene with the transformation rates recording in over more than 90% of the pancreatic, 40% in colorectal, and over more than 30% in lung cancers.

Speaking on the matter, the head of global cancer research at Boehringer Ingelheim, Norbert Kraut cited that the patenting of Lupin’s MEK inhibitor allows the company to pair it with the innovative KRAS inhibitors for the creation of advanced treatment concepts offering highly effective and reliable responses for the cancer patients.

Meanwhile, it has been claimed that Lupin is also entitled to obtain a royalty on sales of the product while retaining the commercial rights to the program in India.

Source credit: https://www.livemint.com/companies/news/lupin-signs-700-million-deal-with-boehringer-ingelheim-to-develop-cancer-drug-1567610208831.html

About Author

Mateen Dalal    

Mateen Dalal

Despite working as a professional testing engineer, Mateen Dalal always held a liking for content creation. Following his passion, he now pens down articles for itresearchbrief.com and a couple of similar portals. Mateen is a qualified electronics and telecommunicat...

Read More>>

More News By Mateen Dalal

Tech giant IBM partners with Japanese industry on quantum computing
Tech giant IBM partners with Japanese industry on quantum computing
By Mateen Dalal

International Business Machines Corp, the U.S. tech firm has announced its partnership with Japanese...

Repare Therapeutics doses first patient in Phase 1/2 trial of RP-3500
Repare Therapeutics doses first patient in Phase 1/2 trial of RP-3500
By Mateen Dalal

This trial will evaluate RP-3500 both as a monotherapy and in combination with talazoparib, Pfizer&r...

LGM Pharma acquires Nexgen’s formulations development business
LGM Pharma acquires Nexgen’s formulations development business
By Mateen Dalal

LGM Pharma, an innovation-driven API, and procurement specialist has reportedly announced that it ha...